Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 6:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: insulin aspart Clear all
Withdrawn Phase 2Phase 3 Interventional

Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pATIENTS (Pts) With Type 1 and Type 2 Diabetes

NCT00228904
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
Placebo, Pulsatile IV insulin delivery (humalog, humulin, novolog)
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
20 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Jun 7, 2026, 6:18 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM

NCT06547619
View directory record Official record
Conditions
Gestational Diabetes, Endothelial Dysfunction, Physical Inactivity
Interventions
Insulin aspart
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

NCT01365507
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Concord, California • Los Angeles, California • Montclair, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Jun 7, 2026, 6:18 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes

NCT05946785
View directory record Official record
Conditions
Gestational Diabetes, Vascular Endothelial Function
Interventions
Acetylcholine, insulin aspart
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 4 Interventional Results available

Insulin Pump to Multiple Daily Injection Transition Clinical Trial

NCT03987191
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Multiple daily ijnection using Insulin Degludec and Insulin Aspart
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

NCT00309244
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
80
States / cities
Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 3 Interventional Results available

IDegLira HIGH Trial

NCT03737240
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
IDegLira, Insulin Degludec (U-100), Insulin Aspart
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Jun 7, 2026, 6:18 AM EDT
Terminated Not applicable Interventional Results available

Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH

NCT00564018
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin detemir, Glargine, NPH
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 4 Interventional Results available

Insulin Glargine "All to Target" Trial

NCT00384085
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glulisine, Insulin Glargine, Premixed Insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years to 80 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2011 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 4 Interventional Results available

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

NCT01524705
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin Glargine, Metformin, Prandial insulin, Exenatide
Drug
Lead sponsor
University of Washington
Other
Eligibility
40 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 2 Interventional Results available

Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting

NCT01755416
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Closed loop with sensor and Insulin, Closed loop with sensor, Insulin and Liraglutide
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Jun 7, 2026, 6:18 AM EDT
Withdrawn Phase 4 Interventional

Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes

NCT02811484
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide-LAR plus Dapagliflozin placebo, Exenatide-LAR plus Dapagliflozin, Insulin Titration, Behavioral Therapy
Drug · Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jun 7, 2026, 6:18 AM EDT
Active, not recruiting Phase 4 Interventional

Oral Anti Diabetic Agents in the Hospital

NCT04416269
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM)
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 3 Interventional

Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy

NCT00598793
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, insulin glargine, metformin, pioglitazone
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
27
States / cities
Concord, California • Los Angeles, California • Walnut Creek, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 1 Interventional

A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump

NCT00115973
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
Interventions
pump, insulin aspart
Device · Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
30 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Chula Vista, California • Miami, Florida • Witchita, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus

NCT01513473
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 17 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 3 Interventional Results available

Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes

NCT01045707
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
41
States / cities
Birmingham, Alabama • Vestavia Hills, Alabama • Concord, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 4 Interventional Results available

Study of Glycemic Control on Liver Transplantation Outcomes

NCT01211730
View directory record Official record
Conditions
Evidence of Liver Transplantation, Hyperglycemia, Rejection
Interventions
Insulin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Early Phase 1 Interventional

Diluted Insulin in Young Children: Bigger Volumes for Smaller Patients

NCT03666065
View directory record Official record
Conditions
Type1diabetes
Interventions
Aspart insulin
Drug
Lead sponsor
Yale University
Other
Eligibility
9 Years to 15 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population

NCT00071448
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin human, insulin lispro, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
6 Years to 18 Years
Enrollment
378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
76
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 4 Interventional Results available

Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Diabetes

NCT00590226
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Detemir + aspart insulin before meals, NPH insulin + regular insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

NCT02443402
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 2 Interventional Results available

Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes

NCT03816761
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Fast-acting insulin aspart, iLet™
Drug · Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Jun 7, 2026, 6:18 AM EDT
Completed Phase 3 Interventional Results available

Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

NCT03874715
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin Aspart SAR341402, Insulin Aspart, Insulin glargine U100
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
33
States / cities
Concord, California • Temecula, California • Ventura, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Jun 7, 2026, 6:18 AM EDT